Paper Details

  1. Home
  2. Paper Details

Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors.

Author: GarciaJoe Gn, LennonFrances E, MambetsarievNurbek, MathewBiji, Moreno-VinascoLiliana, MossJonathan, SalgiaRavi, SieglerJessica H, SingletonPatrick A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Methylnaltrexone (MNTX) synergistically inhibited VEGF-induced human endothelial cell proliferation and migration with the mTOR inhibitors temsirolimus and rapamycin. This could potentially lower the therapeutic dose of mTOR inhibitors.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Recent cancer therapies include drugs that target both tumor growth and angiogenesis including mammalian target of rapamycin (mTOR) inhibitors. Since mTOR inhibitor therapy is associated with significant side effects, we examined potential agents that can reduce the therapeutic dose. ME...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831839/

データ提供：米国国立医学図書館（NLM）

Methylnaltrexone: A Potential Synergistic Agent for Cancer Therapy

This research explores the potential of combining methylnaltrexone (MNTX), a medication that blocks opioid receptors, with mammalian target of rapamycin (mTOR) inhibitors, a class of drugs used to treat cancer. The researchers investigated the effects of this combination on angiogenesis, the process of new blood vessel formation, which plays a crucial role in tumor growth. The study found that MNTX potentiated the anti-angiogenic effects of mTOR inhibitors, suggesting that this combination could potentially enhance the effectiveness of cancer therapies.

Methylnaltrexone: A Synergistic Approach to Cancer Therapy

This research suggests that combining methylnaltrexone (MNTX) with mTOR inhibitors could enhance the effectiveness of cancer therapies. The study found that MNTX potentiated the anti-angiogenic effects of mTOR inhibitors, potentially leading to a more targeted and effective treatment approach. This research highlights the potential for synergistic drug combinations to improve cancer therapy outcomes.

Navigating the Desert of Cancer Treatment

Just as a camel navigates a challenging desert landscape, researchers are constantly seeking new and effective ways to combat cancer. This research offers a promising approach, exploring the synergistic effects of combining methylnaltrexone (MNTX) with mTOR inhibitors to enhance anti-angiogenic therapy. It's like finding a hidden spring in a vast desert – this research could lead to more effective and targeted treatment strategies for cancer patients.

Dr.Camel's Conclusion

This research provides a glimpse into the potential of combining medications to enhance cancer therapy. The synergistic effects of methylnaltrexone (MNTX) and mTOR inhibitors offer a promising avenue for future research and development. It's like finding a hidden oasis in the desert – this research could lead to more effective and less toxic treatment options for cancer patients, providing a glimmer of hope in the fight against this devastating disease.

Date :
  1. Date Completed 2010-06-10
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

20298531

DOI: Digital Object Identifier

PMC2831839

Related Literature

Article Analysis
・Side Effects of temsirolimus
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.